Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2025)

Historic FCF Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 18.29%.

  • Kiniksa Pharmaceuticals International's FCF Margin rose 203000.0% to 18.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.03%, marking a year-over-year increase of 141700.0%. This contributed to the annual value of 6.0% for FY2024, which is 11300.0% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported FCF Margin of 18.29% as of Q3 2025, which was up 203000.0% from 17.76% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's FCF Margin ranged from a high of 62.57% in Q3 2022 and a low of 504.18% during Q2 2021
  • Its 5-year average for FCF Margin is 45.79%, with a median of 4.78% in 2024.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's FCF Margin surged by 4751700bps in 2022 and then crashed by -372600bps in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's FCF Margin stood at 102.08% in 2021, then soared by 108bps to 7.78% in 2022, then tumbled by -34bps to 5.12% in 2023, then soared by 198bps to 15.26% in 2024, then grew by 20bps to 18.29% in 2025.
  • Its FCF Margin stands at 18.29% for Q3 2025, versus 17.76% for Q2 2025 and 16.13% for Q1 2025.